Summary 06-alkylguanine-DNA-alkyltransferase (ATase) activity was measured in extracts of peripheral blood mononuclear cells (PMCs) taken from eight patients at various times during 5 days of oral treatment with temozolomide (150 mg m-2 days 1-5). Pretreatment ATase levels ranged from approximately 70 to 600 fmol per mg of protein. Depletion of PMC ATase was seen within 4 h of the first dose of temozolomide and had a median nadir of 52.9% and values ranging from 44.4% to 71.0% of pretreatment levels. There was a correlation between the extent of ATase depletion (pretreatment minus nadir level) and the pretreatment ATase level (r = 0.97). A progressive depletion of ATase was observed during the 5 days of continuous temozolomide therapy with median ATase activities of 66.3%, 52.5%, 39.5%, 30.5% and 28.9% of the pretreatment values at days 2, 3, 4, 5 and 6 respectively. This suggests that the schedule-dependent antitumour activity of temozolomide seen in experimental models and clinics may be related to a cumulative depletion of ATase.
Temozolomide (CCRG 81045; M&B 39831; NSC 362856) was recently selected for clinical trials and has shown promising anti-tumour activity against high-grade gliomas, melanoma and mycosis fungoides (Newlands et al., 1992;  O 'Reilly et al., 1993) . In contrast to dacarbazine (DTIC) or CB1O-277, which require metabolic activation, temozolomide undergoes spontaneous chemical degradation to generate the cytotoxic monomethyl triazene, 5-(3-methyl-1-triazeno) imidazole-4-carboxamide (MTIC) (Figure 1 ) (Stevens et al., 1987; Tsang et al., 1991) , which methylates DNA, generating among 12 other DNA lesions 06-methylguanine (06-MeG). There is increasing experimental evidence to suggest that the anti-tumour activity of this class of drugs is linked to the alkylation of the 06 position of guanine in DNA and that endogenous expression of 06-alkylguanine-DNA alkyltransferase (ATase) may be a major factor in resistance to such agents (D'Incalci et al., 1988; Margison & Connor, 1990 ; Pegg & Byers, 1992) ; ATase transfers the methyl group from 06-MeG to an internal cysteine residue in an autoinactivating, stoichiometric reaction. A similar mode of drug resistance applies to the chloroethylating nitrosoureas; ATase prevents the formation of the cytotoxic interstrand cross-links which are produced in a two-step reaction from the monoadduct 06-chloroethylguanine, which has itself been shown to be a substrate for ATase (Tong et al., 1982; Gonzaga et al., 1992; Baer et al., 1993) . The strongest evidence for the cytotoxic effects of 06-alkylguanine in DNA comes from experiments which show that the expression of a transfected prokaryotic or eukaryotic ATase cDNA in mammalian cells protects them against the toxic effects of these agents (Brennand & Margison, 1986; Kataoka et al., 1986; Samson et al., 1986; Jelinek et al., 1988; Kaina et al., 1991) .
While the majority of human tumours examined so far express ATase activity (D'Incalci et al., 1988) , it is possible to sensitise resistant tumour cells in culture or xenografts by pretreatment with methylating agents (Zlotogorski & Erickson, 1983 , 1984 Gibson et al., 1986) or the modified base 06-benzylguanine (Dolan et al., 1991) , which renders them sensitive to the cytotoxic effects of subsequent treatment with methylating or chloroethylating agents. Two-to 12-fold increases in sensitivity to these agents have been observed with tumour cell lines which have high levels of AT4se: these include colon (Karran & Williams, 1985; Baer et al., 1993) , melanoma (Dempke et al., 1987) , glioma (Aida et al., 1987; Baer et al., 1993) , breast (Baer et al., 1993) and leukaemic cell lines (Gerson et al., 1988 (Lee et al., 1991 (Lee et al., , 1992 (Lee et al., , 1993a . ATase depletion was also seen in the tumour biopsies of patients receiving the latter treatment schedule (Lee et al., 1992) . Furthermore, using DTIC, very large inter-patient variations in the extents and rates of ATase depletion were observed (Lee et al., 1991 (Lee et al., , 1993a . In the present study we therefore examined the kinetics of ATase depletion in PMCs of eight patients with metastatic melanoma treated with the direct-acting agent temozolomide on five consecutive days. In five patients, changes in PMC ATase levels were also measured at various times during the 24 h after the first dose of temozolomide. In contrast to daily temozolomide administration, a single intravenous bolus of this drug was not associated with any tumour xenograft response in rodent models (Stevens et al., 1987) or in clinics (Newland et al., 1993) and we have therefore also compared ATase levels during 24 h of a single dose of temozolomide with those after 1-5 days of treatment. ing daily temozolomide (150 mg m2 daily from days 1 to 5). Blood was dispensed into 20 ml universal containers containing 0.5 ml of 0.5% EDTA and kept at 4°C before isolation of PMCs. Signed informed consent was obtained following the guidelines of the local health authority ethical committee. The phase II trial of temozolomide was carried out under the auspices of the Cancer Research Campaign (UK) Clinical Trials Committee.
Materials and methods

Chemicals
Isolation of PMC, A Tase extraction and assay This was carried out as described previously (Lee et al., 1991) . Briefly, the PMCs were isolated by centrifugation on Ficoll (Pharmacia, Uppsala, Sweden) (Boyum, 1968) (Figure 4) . The corresponding data from Lee et al. (1991, 1992) are also presented in Figure   4 and correlation coefficients of 0.88 and 0.96 were calculated for DTIC and CB10-277 respectively.
Discussion
In the present study, we clearly demonstrate that temozolomide is effective in depleting ATase activity in PMCs and that the nadir of activity following a single dose is around 2-6h after treatment (Figure 2) . If the ATase depeletion (pretreatment minus nadir levels) seen had been a consequence of temozolomide-mediated methylation of DNA in PMCs and the subsequent autoinactivation of ATase by the repair of 06-MeG thus generated, it would have been predicted that, particularly with an agent not requiring metabolic activation, the actual amount of ATase inactivated in this way would be relatively constant, assuming that drug uptake and ATase resynthesis rates were consistent. However, we found that the extent of ATase inactivation varied Figure 3) . NM, not measurable. considerably from patient to patient, but that there was a strong correlation between the extent of ATase depletion and the pretreatment ATase level. Although ATase depeletion would be expected to occur via methylation of DNA in PMCs by temozolomide, the possibility that this non-stoichiometric depletion of ATase was due to a direct effect of temozolomide on the ATase itself cannot be dismissed. Previous studies have shown that inactivation of partially purified human ATase from CEM cells can occur in vitro following incubation with a variety of alkylating agents, including MNU, streptozotocin, BCNU, chlorozotocin, CCNU and MeCCNU, and, of the agents tested, methylmethanesulphonate was the most effective, producing 50% inactivation at 70 JM (Brent, 1986) .
Reanalysis of earlier results using DTIC and CB10-277 (Lee et al., 1991 (Lee et al., , 1992 also shows a correlation between pretreatment ATase levels and the amounts of ATase inactivated (Figure 4) . Here too, the depletion may therefore be a consequence of the direct reaction of the corresponding metabolites with PMC ATase. That the kinetics of ATase depletion with temozolomide were very similar to that observed with DTIC (Lee et al., 1991) and CB1O-277 (Lee et al., 1992) , both of which require metabolic activation in order to produce a methylating species (Figure 1) , suggests that the process of metabolic activation of the latter agents occurs very rapidly and might not be the rate-limiting step in ATase depletion. If ATase depletion by alkylating agents in vivo is predominantly a direct effect and not unique to PMC, one possible consequence might be that the extent of ATase inactivation would be greatest in those cells and tissues expressing the highest levels of enzyme. Thus, in tumour cells which can express high ATase levels (Dolan et al., 1991) , sensitisation to killing by alkylating agents might be more extensive than in bone marrow, which generally expresses low levels of ATase (Gerson et al., 1985) . Indeed, extrapolation of the data in Figure 4 suggests ATase levels were between 14.4% and 52.5% of the pretreatment values (Figure 3) . There was little inter-patient variation in the percentage decrease in ATase activity during the schedule, despite wide variations in pretreatment ATase levels, suggesting that depletion was possibly a direct effect on ATase.
It has been shown that the anti-tumour activity of temozolomide in tumour-bearing mice is schedule dependent (Stevens et al., 1987) , and a similar finding was reported with 51 patients treated with temozolomide (Newlands et al., 1992) . Thus, improved therapeutic effectiveness was noted when temozolomide was given daily for 5 days compared with single-dose administration. It does not seem unreasonable to suggest that the greater effectiveness of the daily treatment is related to the more extensive depletion of ATase, assuming that a similar effect occurs in the tumour cells. While tumour tissue has not been assessed in the present study, we have previously shown that CB1O-277 is able to deplete ATase levels in both PMCs and melanoma (Lee et al., 1992) .
If tumour sensitisation is a consequence of ATase depletion, then it might be speculated from the present results that response to treatment would be more extensive if the temozolomide was given every 2-6 h, corresponding to the ATase nadir found here after a single dose, rather than every 24 h, when recovery of ATase activity can occur. Indeed, in the treatment of melanoma with DTIC/fotemustine combinations, the schedule of fotemustine 4 h after DTIC was designed to exploit the anticipated nadir of ATase activity produced by DTIC (Lee et al., 1991) and produces better response rates than the individual agents given alone (Lee et al., 1993b) . The possibility therefore of giving a chloroethylating agent 2-6 h after the last of five doses of temozolomide given every 2-6 h also seems worthy of consideration.
